fda warning letter glp-1 october 2025 Week Ending October 31, 2025: Featuring a Panel of FDA Compliance Leaders Discussing Key Current Concerns FDA is moving to restrict

Frequently Asked Questions Can I safely take GLP-1 medications if I have active ulcerative colitis

GLP-1 1(2.5mg) 7,000 7,700 1(5.0mg) 12,000 13,200 GLP-1 GLP-1 GLP-1 GLP-1 GLP- GLP-1 01. GLP-1 02. 03. GLP-1 GLP-1 BMI 3 2GIPGLP-1-1GIPGLP-1 2GIPGLP-1GLP-1 1 12.5mg2.5mg45mg15 mg4 GLP-197FDAGLP-11 11 0.611.2mg11.8mg 1.8mg GLP-1 GLP-1 111 1() 3~4 0.25mg40.5mg 40.5mg1.0mg 34 GLP-1 11 GLP-1 GLP-1 GLP-1 Q 1 A 1 Q A GLP-112122 Q A Q A 40 Q A GLP-12 92(BMI)27 Q A GLP-112122 Q A GLP-111 Q 1 A GLP-11180.630 Q A GLP-1 Q A FDA GLP-1

doi: 10.3390/brainsci13111503

In the STEP 1 extension trial, most people regained a significant amount of weight within a year, though not everyone, and not the same amount

If approved, oral semaglutide could become the first oral GLP-1 therapy available for children and adolescents

Yet current research on the medications is just scratching the surface, says Marty Lerner, PhD, founder of Milestones, an eating disorder recovery program based in Florida